Spots Global Cancer Trial Database for Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Official Title: A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Study ID: NCT02617849
Conditions
Study Description
Brief Summary: This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jewish General Hospital, Montreal, Quebec, Canada
Hopital Notre-Dame, Montreal, Quebec, Canada
Contact Details
Name: Wilson Miller, MD, PhD
Affiliation: Jewish General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Rahima Jamal, MD, PhD
Affiliation: CHUM, Hopital Notre-Dame
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
